Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases

Hafeez, Umbreen, Gan, Hui K, Scott, Andrew M · 2018 · Current Opinion in Pharmacology

Abstract

HighlightsMonoclonal antibodies are effective treatment for various cancers and autoimmune diseases.Immune checkpoint therapy in cancer has emerged as a potent therapeutic approach.Autoimmune disease control with monoclonal antibodies is highly successful.Resistance mechanisms have emerged as a major issue in therapeutic efficacy. &NA; Since Nobel laureate Paul Ehrlich proposed the concept of magic bullet in 1906, Köhler and Milstein discovered Hybridoma technology in 1975, and Greg Winter pioneered the technique to humanize monoclonal antibodies in 1988, monoclonal antibodies have been successfully developed to treat medical illnesses. Monoclonal antibodies are effective treatments for inhibition of alloimmune reactivity, haematological malignancies, solid organ malignancies, viral illnesses and are also used as antiplatelet therapy. Their successful use in cancer and autoimmune diseases in humans have made them one of the fastest growing classes of new drugs approved for these indications in last few decades. This review focuses on the role of monoclonal antibodies as an immunomodulatory therapy against cancer and autoimmune diseases, the strategies used to enhance efficacy, and how resistance mechanisms are being addressed to improve therapeutic outcomes for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.coph.2018.05.010

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 176

Metadata

Authors
Hafeez, U., Gan, H. K., & Scott, A. M.
Venue
Current Opinion in Pharmacology
Publisher
Elsevier BV
Published
2018-08
Volume
41
Pages
114-121
ISSN
1471-4892 (ISSN-L)
OpenAlex
W2807443486
Cited by
176
References
22
FWCI
2.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. https://app.cochat.ai/papers/10.1016/j.coph.2018.05.010
The paper
Hafeez, U., Gan, H. K., & Scott, A. M. (2018). Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology. https://doi.org/10.1016/j.coph.2018.05.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.